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Small molecule aggregators form aggregates or colloids at 
micromolar concentrations in buffered solutions.
1
 Aggregators 
are commonly found and widely distributed within large 
compound libraries.
2
 These compounds are frequently identified 
as inhibitors, and they are often prevalent early in drug discovery 
campaigns.
3
 Such compounds may be problematic to identify as 
false positive because the mechanism by which they inhibit target 
proteins and enzymes is nonspecific, producing results similar to 
true positives in a variety of assays.
4 
There are hallmarks for aggregator-based inhibition. 
Aggregators often show non-competitive inhibition,
5
 as well as 
slowly reversible,
6
 and time-dependent inhibition.
7
 Of course, 
true positives can also show these characteristics. However, more 
particular to aggregators, inhibitor potency as indicated by the 
kinetic parameters of inhibition, often varies with enzyme 
concentration.
7
 Detergents often reduce or even eliminate 
inhibition by aggregate-forming false positives.
8 
In addition, 
these compounds are non-specific,
9
 inhibiting multiple unrelated 
enzymes,
10-12
 and they show dose-response curves with high Hill 
slopes.
13
 Structure-activity relationships (SAR) may be 
ambiguous
14
. Finally, particles of varying sizes may be detected 
in aqueous solutions containing these compounds.
15,16
  
Fourteen compounds containing oxadiazole-amide (Table 1) 
and aminobenzothiazole scaffolds (Table 2) were evaluated in 
this study. These compounds originated from a library of 404 
compounds selected through the Tuberculosis Antimicrobial 
Acquisition and Coordinating Facility (TAACF) Program of the 
National Institute of Allergy and Infectious Diseases (NIAID). 
This set of 404 compounds were in M. tuberculosis H37Rv 
screens performed at Southern Research Institute (SRI).
17-19
 The 
collection was further tested in vitro against M. tuberculosis 
shikimate kinase (MtSK). Out of 404 compounds 14 hits 
displayed >90 % inhibition at concentrations below 50 µM.
20 
In this study, we investigated aggregate forming properties of 
compounds in the 14 MtSK hit set, utilizing ESI-LC-MS, proton 
nuclear magnetic resonance spectroscopy (
1
H-NMR), dynamic 
light scattering (DLS), transmission electronic microscopy 
(TEM). Centrifugation assays were utilized to detect precipitate 
formation and qualitatively determine the solubility of 
compounds. The tendency of these compounds to form 
aggregates was predicted computationally, using the aggregate 
advisor tool and MycPermCheck software. We have used two 
controls. The MtSK-specific inhibitor, 3-methoxy-4-{[2-({2-
methoxy-4-[(4-oxo-2-thioxo-1,3thiazolidin5ylidene)methyl] 
phenoxy}methyl)benzyl]oxy}ben-zaldehyde (Fig. S1) was 
utilized in all experiments except 
1
H-NMR. Riluzole, a non-
aggregator (Fig. S3), was used in 
1
H-NMR assays. 
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Single dose high-throughput screening (HTS) followed by dose-response evaluations is a 
common strategy for the identification of initial hits for further development. Early 
identification and exclusion of false positives is a cost-saving and essential step in early 
drug discovery. One of the mechanisms of false positive compounds is the formation of 
aggregates in assays. This study evaluates the mechanism(s) of inhibition of a set of 14 
compounds identified previously as actives in Mycobacterium tuberculosis (Mt) cell 
culture screening and in vitro actives in Mt shikimate kinase (MtSK) assay. Aggregation of 
hit compounds was characterized using multiple experimental methods, LC-MS, 1H-NMR, 
dynamic light scattering (DLS), transmission electron microscopy (TEM), and visual 
inspection after centrifugation for orthogonal confirmation. Our results suggest that the 
investigated compounds containing oxadiazole-amide and aminobenzothiazole moieties are 
false positive hits and non-specific inhibitors of MtSK through aggregate formation. 
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Table 2. 2-Aminobenzothiazole analogs (11-14) 
8-10 
1-3 
4-5 
6-7 
Figure 1. A. An extracted ion chromatogram of shikimate-3-phosphate in different 
conditions for compound 3. B. ESI-MS spectrum showing shikimate-3-phosphate 
(S3P) ionic mass. C. Chemical Structure of shikimate-3-phosphate (S3P). 
Table 3. Effect of 0.01% Triton X-100 on MtSK inhibition by oxadiazole-amide 
and aminobenzothiazole at 100 µM and control at 30 µM. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Compared to reactions that contained only MtSK and its 
substrates, inclusion of any one of the compounds resulted in a 
substantial decrease in S3P production (Table 3) as observed in 
extracted ion chromatograms (Fig. 1), This indicates inhibition; 
however, the inhibitory effect was completely eliminated if 
Triton X-100 was also present or if MtSK concentration in the 
assays was increased from 0.02 to 0.2 μM. These data indicate 
that inhibition by these compounds is due, at least in part, to their 
propensity to form aggregates that non-specifically disrupt MtSK 
structure. Accordingly, inclusion of Triton X-100 limits 
formation of aggregates, and therefore, eliminates that 
contribution to MtSK inhibition. Likewise, inhibition by 
aggregators is known to be attenuated by an increase in enzyme 
concentration. Consistent with these findings, inhibition by a 
known specific inhibitor of MtSK as a control was not eliminated 
either by the inclusion of detergent or increasing the 
concentration of MtSK in activity assays. Interestingly, even the 
control showed potential signs of aggregation, albeit to a much 
lesser extent than the other compounds. Addition of Triton X-100 
increased % inhibition by the control when the concentration of 
MtSK was 0.2 μM. One explanation is that aggregation was 
disrupted in the biochemical buffer, permitting the control to 
behave as a specific inhibitor in the classical sense.  
 
 
 
 
 
 
 
 
 
 
 
 0.02 µM MtSK 0.2 µM MtSK 
  Without 
  Triton X-100 
With 
 Triton X-100 
Without 
Triton X-100 
      With 
Triton X-100 
Structure Inhibition % Inhibition % 
3 
4 
7 
14 
95± 2 
91.6±0.5 
90±1 
97.4± 1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 Control 96± 1 98± 1 55± 2 83± 2 
 
Compound R1 R
2               R3 
 
11 
   
4-Ethyl 
12  
 
    5,7-dimethyl 
 
13       4,6-difluoro 
14  H 6-Acetylamino 
 
Compound R1 R
2 R3 
1 n-butyl 
  
2 Ph-thio-Ethyl 
  
3 Ph-CH=CH 
  
Compound     R1 R
2 R3 
4 2,4-diMe, 
X=O 
  
5 2,5-diMe, X=S   
Compound R1 R
2 R3 
6 2,4 diMe-Ph 2-Cl  
7 2-Cl-Ph 3-O-Ph  
Compound    R1 R
2     R3 
    8 4-Br-Ph t-bu  
    9 2-furanyl 4-EtS-Ph  
         10 2,4-diMe-Ph Ph-O-Ethyl 
 
Table 1. Oxadiazole-amide analogs (1-10) 
11-14 
  
Table 5. cLogP and solubility values of test compounds calculated with 
Schrödinger software package 
 FOSA= The hydrophobic part of the solvent accessible surface area (saturated 
carbon and attached hydrogen atoms), cLogP= Calculated logarithm of 
compound’s partition coefficient between n-octanol and water, PISA= portion 
of the solvent accessible surface area responsible for π interaction, and 
accptHB= Number of hydrogen bond acceptors. 
With all compounds, a sharp transition to full inhibition 
occurred over a very narrow range of concentration (Fig. 2) as 
reflected by Hill coefficients substantially greater than 1. This is 
a common pattern among non-specific inhibitors.
5
 Compounds 3, 
4, 7, and 14 incubated with 0.015 μM MtSK showed IC50 values 
of 58.4, 65.72, 38.73, and 60.64 μM, respectively (Table 4). Hill-
slope values were 4.7, 8.5, 2.4, 6.1, and 6.7 for compounds 3, 4, 
7, 14, and the control, respectively. Finally, we visually inspected 
concentration-response curve of compound 3, reported 
previously,
20 
which showed similar phenomenon to compound 3 
in this study. Notably, the control exhibited a similarly steep Hill-
slope, this is likely due to the presence of aggregates at higher 
concentration. The effect of Triton X-100 addition to 0.2 mM 
MtSK experiments in Table 3 supports this conclusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5 lists computed cLogP (partition coefficient) and 
LogS (solubility) for the fourteen compounds (Schrödinger 
software). Computed parameters suggest that compound 11 is 
the most lipophilic (cLogP 5.148) whereas compound 4 the least 
hydrophobic (cLogP 1.736). Within this set compound 2 is 
predicted as least soluble (solubility: -6.854) and compound 9 as 
most soluble (solubility: -4.246).  
 
 
 
 
With the MycPermCheck tool, Mtb cell wall permeability 
was predicted for the set of fourteen compounds based on four 
descriptors listed in Table 6. The predicted permeability was 
color coded as follows: high permeability scores are colored 
green (0.82 < score < 1), medium permeability orange (0.55 < 
score < 0.82) and poor permeability red (score < 0.55). 
Interestingly, eight compounds were predicted to be highly 
permeable, namely, 2, 3, 6, 7, 9, 11, 13, and 14. These 
compounds are also associated with higher LogP values within 
the set. Considering one descriptor only will not guarantee high 
permeability values. Instead, all descriptors should be taken into 
consideration. As described by Merget et al.,
21
 the computational 
tool predicts passive diffusion transportation only, which is a 
limitation of the tool, this suggests that compounds 1, 4, 5, 8, 10, 
and 12 traverse Mtb cell wall by other mechanisms. Although the 
permeability prediction tool is useful for predicting compounds 
that are expressing their activity through cell wall penetration, 
absolute confirmation is not expected. Therefore, we suggest that, 
from the set of 14 compounds, the most active compounds, 4, 6, 
7, 8, 9, 11, and 14 (Table 7) should be further investigated so as 
to understand their mechanism of action. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound IC50 (μM)
  
MtSK 0.015 μM 
3 58.4 ±0.02 
4 65.72 ±0.01 
7 38.73 ±0.02 
14 
Control 
60.64 ±0.04 
10.10 ±0.02 
Structure cLogP Solubility
* 
1 3.637 -5.193 
2 4.306 -6.854 
3 4.063 -6.247 
4 1.736 -4.329 
5 2.206 -4.777 
6 3.553 -5.466 
7 4.446 -6.211 
8 2.839 -4.544 
9 2.703 -4.246 
10 3.728 -5.761 
11 5.148 -6.02 
12 3.822 -4.688 
13 4.262 -5.003 
14 3.665 -6.102 
Control 5.162 -8.197 
Compound 
number 
 
Score FOSA LogP    PISA accptHB 
11 1 201 5.148 415 6.5 
7 1 0 4.446 513 5.5 
13 0.998 64.3 4.262 352 6.5 
3 0.997 209.11 4.063 355 5 
2       0.991 253 4.306 329 5.5 
6       0.966 160.88 3.553 290 5 
9  0.87 131 2.703 313 6 
14  0.865 181.64 3.665 263 6.5 
10  0.715 301.72 3.728 267 5.75 
5  0.152 160.88 2.206 211 6 
12  0.118 363.25 3.822 92 2 
8  0.136 205.12 2.839 173.3 5 
4  0.057 160.89 1.736 221.9 6.5 
1  0.024 391.26 3.637 122 5 
 Control 0.627 229 5.162 309 7.5 
Compound 14
-7 -6 -5 -4 -3
0
50
100
Log [Compound 14 (M)]
IC50= 16.4 µM ± 0.04308
%
 I
n
h
ib
it
io
n
Table 4. IC50 values of non-specific inhibitors against 0.015 μM purified 
MtSK.  
Table 6. Mtb cell wall permeability prediction of oxadiazole-amide and 2-
aminobenzothiazole compounds. 
 
Figure 2.  Concentration response-curves values of compounds 3, 4, 
7, and 14 and control. All show curve steepness. 
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Table 7. Anti-Mtb phenotypic activity of oxadiazole-amide and 2-
aminobenzothiazole 
 
Table 8. Scattering intensities and average particle sizes of test compounds with 
significant DLS signals in ammonium acetate pH 7.6 
 
Compound 
number 
 
TB IC90(μg/ml)H37Rv 
*Activity level 
1 3.04 Medium 
2 1.93 Medium 
3 1.68 Medium 
4 0.69 High 
5 3.09 Medium 
6 < 0.20 High 
7 0.86 High 
8 < 0.20 High 
9 0.71 High 
10 1.8 Medium 
11 0.83 High 
12 1.75 Medium 
13 2.38 Medium 
14 < 0.20 High 
 
 
For the evaluation of micelle formation, we selected 
compound 9, which was predicted most soluble among the 
fourteen compounds. Protons attached to the methyl and ethyl 
groups present in its aliphatic side chain (see Fig. S2) were 
selected to monitor peak broadening since these were easily 
recognized and differentiated in 
1
H NMR spectra. Moreover, the 
aliphatic chain is lipophilic and may contribute to the formation 
of aggregates of this compound in the buffer solution.  
An increasing contribution from peak broadening was 
observed in 
1
H-NMR spectra with increasing concentration of 9  
from 6.25 µM up to 200 µM (Fig 3A), indicating aggregate 
formation. The MtSK inhibitory potency of compound 9 was 
previously determined in our laboratory
20
 and reported having the 
IC50 value of 20.73 µM.    
1
H NMR spectra of compound 9 in Fig. 
3A showed peak broadening (aggregation) even at 6.25 µM, 
which indicates that MtSK inhibition by compound 9 was non-
specific, likely due to formation of aggregates. In contrast, 
riluzole (Fig. S3), a glutamate blocker for treatment of 
amyotrophic lateral sclerosis
22
 and a known non-aggregator,
23
 
showed no peak broadening across a concentration range from 
12.5 – 200 µM (Fig. 3B).  Signal intensities displayed sharp 
resonance and a gradual reduction of signal intensity in 
alignment with the compound dilution. No signal shifts were 
observed.  Normal NMR resonances should be sharp, and shift in 
signals should not be expected. There should be no changes in 
the number and shape of the resonances should be constant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We obtained two parameters from our DLS studies, 
intensity of scattered light and average particle size, both of 
which increase when aggregation occurs. Compounds 1-14 at 
100 µM were dissolved in two media, ammonium acetate buffer 
(Table 8) and water (Table S1). In either solution, scattering 
intensity and particle size were both large, suggesting 
aggregation. In comparison, when 0.01% Triton X-100 was also 
included, light scattering intensity and particle size were both 
substantially diminished, indicating dissolution of aggregates 
formed by these compounds. Indeed, in ammonium acetate the 
average test compound at 100 µM showed a scattering intensity 
of 292 k count and particle size of 1731 nm in the absence of 
Triton X-100. Conversely, in the presence of 0.01% Triton X-
100, they displayed an average scattering intensity of 136 k 
count and particle size of 343 nm. Nearly identical results were 
observed in water (Table S1). These phenomena were in stark 
contrast with 3-methoxy-4-{[2-({2-methoxy-4-[(4-oxo-2-thioxo-
1,3thiazolidin5ylidene)methyl]phenoxy}methyl)benzyl]oxy}ben
-zaldehyde, the MtSK-specific control inhibitor, which did not 
scatter light and did not form particles in either medium until a 
concentration of 30 µM (three-fold higher than the IC50 from 
Fig. 2). This may be indicative of some aggregation, but even 
under these conditions both k count and particle size were 
substantially smaller than the 14 test compounds.  
 
Compound 
Concentration 
 
100 µM 
 Without 
Triton X-100 
                            With 
                   Triton X-100 
Structure Intensity  
(Counts) 
Size  
(nm) 
Intensity 
(k Counts) 
Size 
(nm) 
1 280 1432 131 255 
2 340 2005 158 480 
3 310 1820 141 390 
4 190 851 83 131 
5 240 986 85 151 
6 270 1321 115 212 
7 350 2850 180 516 
8 260 1211 100 201 
9 250 1151 100 185 
10 300 1620 123 354 
11 400 3776 286 817 
12 300 1750 139 373 
13 321 1934 150 470 
14 285 1531 122 271 
           Without 
         Triton X-100 
                         With 
             Triton X-100 
 
Control 
Intensity  
(k Counts) 
     Size  
     (nm) 
           Intensity 
          (kCounts) 
Size 
(nm) 
30 µM 30 80 5 0 
10 µM 4 0 4 0 
 3 µM 0 0 0 0 
 
To corroborate our DLS investigation, we used 
transmission electron microscopy (TEM) to image particles 
formed by each of our 14 candidate compounds in aqueous 
ammonium acetate. The behavior of compound 14 was typical 
(Fig. 4A and B). In the absence of Triton X-100, large 
aggregates were observed (mean size = 0.7µm) (Fig. 4A); 
however, when Triton X-100 was added, the aggregates were 
disintegrated, producing particle sizes in the submicron range 
(Fig. 4B). This confirms the tendency of the compounds toward 
aggregation and the interference of a detergent like Triton X-100 
in that process. At 30 µM, the control exhibited smaller particle 
size (mean = 0.1µm) (Fig. 4C). Inclusion of Triton X-100 
resulted in the dissolution of aggregates, producing a mean size 
particle of 0.005 µm (Fig. 4D). 
 
*Activity level, high: <0.1 – 1.6, medium: 0.9 – 10.3, and low: 
6.3 - >50 
 
Figure 3. A. 1H NMR spectra of compound 9 producing micelle formation (peak 
broadening) from 200 µM down to 6.25 µM. Methyl group signal with a chemical shift at 
721.6 Hz (Upfield), and ethyl group represent a signal with a chemical shift at 1776.0 Hz 
(Downfield). B. 1H NMR spectra of a non-aggregator, riluzole (dilutions 200 µM-12.5 
µM). Aromatic signals from 4150 Hz to 4490 Hz, no micelle formation, sharp signals as 
expected, and a gradual decrease of intensity.  
the compound was diluted. 
  
Figure 4. Images visualized by transmission electron microscopy: A. Compound 
14 100 µM formed aggregates with an average size of 0.7 µm (Bar = 1 µm). B. 
Disrupted aggregates of compound 14 with an average size of 0.03 µm were 
disrupted by 0.01% v/v Triton X-100 (Bar = 250 nm). C. Control at 30 µM 
exhibited aggregation with an average size of 100 nm (Bar = 500 nm).  D. 
Control in presence of 0.01% v/v Triton X-100 showed very small particles in 
the nanometer range with an average size of 5 nm (Bar = 500 nm). All samples 
were dissolved in ammonium acetate buffer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When each of the fourteen compounds (50 and 100 M in 
buffered solution) was subjected to centrifugation (14,000  g for 
40 min.), pellets were evident by visual inspection (data not 
shown).  
Among the fourteen compounds, 1, 2, 3, 5, 6, 7, 8, 9, 10, and 
13 were predicted to form aggregates or micelles, based on the 
aggregator advisor tool database. Compound 1 had the highest 
percentage, 93% of similarity to a previously reported 
aggregator, whereas compounds 8 and 13 had the lomtwest, 72% 
of similarity within the set. Although compounds 11, 12, 14, and 
the MtSK-specific inhibitor control did not resemble any 
previously described aggregator in the aggregator advisor tool 
database,
24
 these were flagged as potential aggregators and 
suggested for experimental evaluation. Our results clearly show 
that 14 (Fig. 4) as well as 11 and 12 (Table 8) form aggregates. 
However, the MtSK-specific control inhibitor showed only a 
limited capacity to form aggregates (Fig. 4) and (Table 8), and 
this was at a concentration three-fold greater than the IC50. 
Aggregation is a likely contributor to inhibition of MtSK by 14 
(see Fig. 4). Compound 4 was the only compound from the list 
that was not flagged. Nevertheless, our approach was able to 
identify even 4 as an aggregating inhibitor. 
An interesting aspect of the fourteen compounds investigated 
here is that all of them have IC90 values < 4 μg/ml in M. 
tuberculosis H37Rv whole-cell screens (Table 7).
17-19
 At first 
glance, this is at variance with the data we present here, showing 
the strong propensity of all of these compounds to form 
aggregates and inhibit MtSK on that basis. However, taken 
together, these data reveal two important conclusions. First, it is 
likely that complex biological media/intact cells contain certain 
proteins or other factors that ameliorate aggregate formation or 
otherwise facilitate compound delivery to the intracellular milieu. 
This is consistent with what has been noted elsewhere for some 
known drugs
5
 and confirms that a tendency toward aggregation 
need not be a death sentence for drug development. Second, it 
seems clear that the antitubercular properties of these compounds 
are due to their interaction with a target(s) other than MtSK. 
In this study, fourteen compounds, oxadiazole-amides and 2-
aminobenzothiazole, have been characterized as non-specific 
inhibitors of MtSK due to aggregation. This phenomenon was 
observed across a variety of techniques, including LC-MS, 
1
H-
NMR, DLS, TEM, and centrifugation assays. In general, these 
assays should serve as practical tools to eliminate false positive 
hits in early drug discovery process. Detection of promiscuous 
inhibitors early on saves time and resources. We propose the use 
of LC-MS and NMR based assays to detect aggregation produced 
by false positive compounds. These methods are widely used in 
inhibition studies and routinely available in drug discovery and 
development laboratories. 
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